Fragmented alliance in cancer drugs
Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery, a member of the Almac Group, located in Craigavon, Northern Ireland. "We have been impressed with Beactica’s expertise and capabilities in SPR biosensor-based drug discovery and are looking forward to a fruitful collaboration on these important targets", said Tim Harrison, VP Medicinal Chemistry at Almac Discovery. "We plan to take projects to clinical proof of concept (or earlier) before out-licensing or partnering for further development”. Beactica specialises in surface plasmon resonance (SPR) biosensor- based small molecule interaction analysis and offers partnerships for fragment-based lead generation using its Sprint platform. Founded in 2006 based on research carried out at Uppsala University, Beactica is regarded as a leader in SPR biosensor-based small molecule drug discovery.